<DOC>
	<DOCNO>NCT02616913</DOCNO>
	<brief_summary>This study evaluate single oral dose 150 mg novel food ingredient ( AME001 , R , R-monatin ) effect Fridericia-corrected QT ECG interval ( QTcF ) exceed 10 millisecond ( msec ) . Each subject consume test article ( 150 mg ) , placebo , moxifloxacin ( 400 mg ; positive control ) 3 treatment period .</brief_summary>
	<brief_title>Evaluation Cardiac Effects Novel Food Ingredient Healthy Male Subjects</brief_title>
	<detailed_description>This study specifically design evaluate potential effect ingestion novel food ingredient cardiac safety . The objective fulfil assess cardiac parameter include heart rate , blood pressure , ECG/QT interval healthy adult male subject follow single dose oral administration test article . The primary objective study demonstrate single oral dose 150 mg test article effect Fridericia-corrected QT ECG interval ( QTcF ) exceed 10 millisecond ( msec ) .</detailed_description>
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Nonsmoking healthy male 18 45 year age ; BMI within range 18.0 30.0 kg/m2 , inclusive , body weight ≥60 kg ; Subjects partner childbearing potential agree use dual method contraception Checkin 3 month ( 90 day ) last treatment , provide sperm donation Checkin 3 month ( 90 day ) last administration test article . Double barrier method include : male condom spermicide ; sterile sexual partner ; use female sexual partner intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( e.g . NuvaRing® ) diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive ; Subjects must good health , determine clinically significant relative abnormality identify medical history , full physical examination , vital sign measurement , 12lead ECG , clinical laboratory evaluation ; Subjects must willing able comply study requirement ; Subjects must give write informed consent . Presence history disorder may prevent successful completion study , opinion investigator ; Subjects receive investigational product ( investigational pharmaceutical medical device ) within 30 day prior Day 1 first treatment period ( Checkin ) ; Any cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease clinically significant opinion Investigator ; Any surgical medical condition may interfere absorption , distribution , metabolism , excretion test article ( cholecystectomy appendectomy allow ) ; Any acute disease state ( e.g . nausea , vomit , fever , diarrhea ) within 7 day Day 1 first treatment period ( Checkin ) ; History drug abuse within 1 year Day 1 first treatment period , assessed Investigator , drug abuse define : recurrent use substance result failure fulfill person 's major role obligation work home ; recurrent use physically hazardous situation ; recurrent substancerelated legal problem ; continue use despite persistent recurrent social interpersonal problem cause exacerbated substance ; Admitted alcohol abuse history alcohol use may interfere subject 's ability comply protocol requirement opinion Investigator ; Family history Long QT Syndrome and/or unexplained sudden cardiac death ; Any clinically important deviation normal limit physical examination , vital sign , 12lead ECG , clinical laboratory test result , opinion Investigator ; Electrolyte result Ca , Mg , K outside normal limit ; electrolyte assess Investigator clinical significance subject exclude result deem clinically significant ; QTc duration ≥450 msec base machineread trace Screening . Recalculation QTcF 1 repeat may allow ; repeat may allow discuss agree Medical Monitor ; Positive serologic finding HIV antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibodies ; Positive finding urine drug screen ( e.g . amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) ; History clinically important allergy moxifloxacin ; History significant adverse drug reaction fluoroquinolone ; Use investigational medication within 30 day prior first dose use prescription medication interval 14 day prior Checkin first treatment period completion study . In addition , subject refrain use overthecounter nonprescription medication ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ; except occasional use acetaminophen ) , dietary supplement , within 7 day Day 1 first treatment period ( Checkin ) ; Consumption caffeinecontaining product ( e.g . coffee , tea , chocolate , soda ) alcoholic beverage within 72 hour Day 1 first treatment period ( Checkin ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>